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IL-11R Targeting in Lung CancerAlthough cytotoxic combination chemotherapy is still used
in advanced and metastatic stage and as neo-adjuvant or
adjuvant treatment of earlier stages, target therapies have
been increasingly used in NSCLC toward personalized
treatments.5 Large randomized clinical trials demonstrated
a benefit from the introduction of the antiangiogenic drug
bevacizumab in combination therapy,6 as well as cetuximab
in patients with epidermal growth factor receptoreexpressing
tumors.7,8 Furthermore, small-molecule inhibitors, such as
gefitinib9 or crizotinib,10 are options for NSCLC patients
with epidermal growth factor receptor mutations or echino-
derm microtubule-associated protein-like 4eanaplastic lym-
phoma kinase translocations, respectively. However, despite
improvements in therapeutic approaches, the survival
expectation for patients with advanced NSCLC remains only
16 to 24 months.1 Thus, given the high incidence and rate of
mortality associated with this tumor, new molecular targets
are an unmet need.
Through the selection of circulating combinatorial phage
display libraries in a terminal wean patient with cancer, we
have uncovered new tumor- and vascular-specific molecular
targets.11e13 Among these, the cyclic peptide motif
CGRRAGGSC (single letter code) was validated as a mimic
of IL-11, mapping to a previously unrecognized binding site
that interacts with IL-11 receptor (IL-11R) with consequent
STAT-3 phosphorylation and cell proliferation.14,15 In
addition to our previous work demonstrating elevated levels
of IL-11R in prostate cancer,11 similar data have been
reported in carcinomas of the breast, colon, and stomach;
bone sarcomas; and leukemia/lymphomas.16e20 In preclin-
ical models, the CGRRAGGSC peptide conjugated to a
proapoptotic moiety (CGRRAGGSC-GG-D[KLAKLAK]2)
selectively targeted prostate cancer osteoblastic metastasis,
as well as osteosarcoma metastasis in the lung, while having
no toxic effect on normal surrounding tissues.16,21 This
formulation, termed BMTP-11, underwent evaluation in a
first-in-man phase zero clinical trial, aimed at defining drug
specificity, maximum tolerated dose, and limiting toxicities
with promising pilot results.22
Here, we evaluate IL-11R as a molecular target in human
lung cancer and propose a therapeutic approach based on the
selective targeting of IL-11R. In human samples, we found
increased expression of IL-11R in tumors compared with
adjacent nonmalignant tissues. Overexpressed IL-11R was
exposed on the tumor cell membrane and was present also in
tumor vascular endothelial cells, supporting the ligand-
directed accessibility of this receptor from the circulation.
We demonstrated that in vitro BMTP-11 efficiently targets
and kills a panel of lung cancer cell lines derived from
adenocarcinoma (ADC), squamous cell carcinoma (SCC),
or large cell lung carcinoma. When BMTP-11 was sys-
temically administered in vivo, we observed a significant
delay in the growth of subcutaneous tumor xenografts plus a
reduction in the establishment of pulmonary tumors after tail
vein injection of human lung cancer cells. Taken together,
these results suggest that BMTP-11 could potentially serveThe American Journal of Pathology - ajp.amjpathol.orgas an active targeted drug candidate to be evaluated in
patients with lung cancer.
Materials and Methods
Cell Culture
The human lung cancer cell lines A549, H226, H460, and
H522 were from the ATCC (Manassas, VA); HOP62 and
HOP92 were from the National Cancer Institute, Center for
Cancer Research cell repository (Bethesda, MD). Cells were
cultured at 37C in 5% CO2 and maintained in RPMI 1640
supplemented with 5% fetal bovine serum (ThermoFisher
Scientific, Waltham, MA), 5 mmol/L L-glutamine, and
antibiotics (100 U/mL penicillin G and 100 mg/mL strep-
tomycin; ThermoFisher Scientific).
Flow Cytometry
Exponentially growing cells were harvested, washed with
phosphate-buffered saline (PBS), and resuspended in ice-cold
PBS that contained 1% bovine serum albumin. Human Fc
Receptor Blocking Reagent (Miltenyi Biotec, San Diego, CA)
was added to each cell suspension (20 mL per 1  107 cells)
and incubated for 10 minutes on ice. Next, 20 mL of either
anti-human IL-11Ra-phycoerythrinelabeled antibody (Clone
N-20; SantaCruzBiotechnology,Dallas, TX) or phycoerythrin-
conjugated rabbit IgG isotype control (GeneTex, Irvine, CA)
was added per 1 106 cells in 100mLof PBS that contained1%
bovine serum albumin and incubated at 4C for 1 hour. Sub-
sequently, cells were washed with PBS that contained
1%bovine serum albumin and analyzedwith aBDFACSCanto
flow cytometer (BD Biosciences, Franklin Lakes, NJ).
Cell Viability and Apoptosis Assays
Cells were grown to 95% confluence in 96-well plates (Fisher
Scientific, Pittsburgh, PA). Serial molar concentrations of
either BMTP-11 or nontargeted D[KLAKLAK]2 control were
added to each well to a final molar concentration of 1 to 1000
mmol/L. After incubation at 37C for 18 hours, cell viability
was assessed with the WST-1 assay (Roche Life Sciences,
Indianapolis, IN). Values obtained in test conditions were
normalized to negative controls and were expressed as per-
centage values. Apoptotic cell death was evaluated with the
Annexin V/PI kit (BD Biosciences, San Jose, CA) according
to the manufacturer’s instructions. In essence, 15,000 cells
were seeded into 96-well plates, treated with serial molar
concentrations of either peptide (1 to 1000 mmol/L) for 6
hours, followed by the addition of 4 mL/well of the Annexin
V antibody. Fluorescence was quantified in a ClarioStar plate
reader (BMG Labtech, Ortenberg, Germany). For both as-
says, reverse sigmoidal doseeresponse curves with variable
slopes were fitted, and concentration that inhibits 50% (IC50)
values were calculated with the Prism software version 5.0
(GraphPad Software, Inc., La Jolla, CA).2163
Figure 1 Immunohistochemical validation of IL-11R in human lung
cancer. AeD: Negative control (secondary antibody) (A), grade 2þ (B),
and grade 3þ (C) cytoplasmic IL-11R staining in an exemplary SCC
sample; grade 3þ cytoplasmic IL-11R staining in an exemplary adeno-
carcinoma (ADC) sample (D). E and F: Membrane positivity (arrowheads)
and stromal blood vessel staining (F) in a representative ADC sample
(arrows). G and H: Normal lung from a healthy donor (G) and a lung
cancer patient (nonmalignant tissue adjacent to the tumor; H), arrows
indicate the bronchiolar wall below the basement membrane. Scale barZ
100 mm.
Cardó-Vila et alLung Cancer Mouse Models
Female nude BALB/c mice were from Harlan Laboratories
(Indianapolis, IN). The H460 human lung cancer cell line is
a well-established model, known to produce consistent
subcutaneous tumors and lung tumors after intravenous
administration. A subcutaneous model was obtained by
implantation of 106 H460 cells into the flank; expression of
IL-11R in these tumors was confirmed by immunohisto-
chemistry (IHC). Treatment consisted of injections of 10
mg/kg of either BMTP-11 or nontargeted D[KLAKLAK]2
peptide (n Z 10 per group) at days 3 and 10 after tumor
implantation. Tumor sizes were serially measured with a
digital caliper, and tumor volumes were calculated.23,24 A
lung colonization model was established by tail vein injec-
tion of 106 H460 cells.25e27 Again, expression of IL-11R
was confirmed in lung tumors by IHC staining with an
antieIL-11R antibody. Mice were treated with BMTP-11
(n Z 10) or nontargeted D[KLAKLAK]2 peptide (n Z 9)
as described above in this section and sacrificed 15 days
after tumor cell injection. Lungs were recovered, weighed
on a digital scale, formalin-fixed, and paraffin-embedded.
Ten sections corresponding to different levels of the lungs
were obtained, which were stained with hematoxylin and
eosin. The number of tumors in each slide was determined
by a pathologist. All animal protocols were approved by the
Institutional Animal Care and Use Committee at The
University of Texas MD Anderson Cancer Center, and all
experiments were completed in accordance with institu-
tional guidelines.
Patient-Derived Samples
The retrospective study was approved by the Institutional
Review Board at The University of Texas MD Anderson
Cancer Center. Surgical lung cancer specimens were
obtained from the Lung Cancer Specialized Program of
Research Excellence Tissue Bank. A panel of patient-
derived samples (n Z 368) was collected from 1997 to
2001. A tissue microarray was constructed from triplicate
1-mmediameter cores, punctured from central, intermedi-
ate, and peripheral regions of primary lung cancers
(n Z 327), as described.28,29
IHC Staining
IHC was performed on 4-mm formalin-fixed paraffin-
embedded tissue sections. Antigen retrieval was achieved
by heating in 1 mmol/L EDTA pH 8.0 (ThermoFisher
Scientific), followed by blocking in 3% H2O2 for 15
minutes and Protein Block Solution (Dako Corp., Car-
pinteria, CA; Code X0909) for 30 minutes. The primary
goat anti-human (clone K20; Santa Cruz Biotechnology;
used for human tissues) or rabbit (clone C20; Santa Cruz
Biotechnology; used for mouse tissues) antieIL-11Ra
antibody was incubated for 2 hours. Staining was revealed2164with a secondary antibody and Envision Plus Dual Link-
labeled polymer (Dako Corp.) for 30 minutes, after
which time diaminobenzidine was applied for 5 minutes.
Slides were counterstained with hematoxylin. IL-11R
expression was evaluated by two independent expert
pathologists as described.21,30 Cytoplasmic scores were
obtained by multiplying a 4-value intensity score (0, none;
1þ, weak; 2þ, moderate; 3þ, strong) by the percentage
of positive area. The membrane expression of IL-11R
was quantified as percentage of membrane-positive cells
over a total of at least 200 cells evaluated (Supplemental
Table S1).ajp.amjpathol.org - The American Journal of Pathology
Table 1 Multivariate Analysis for Patients Included in the TMA
Characteristic Frequency count Total frequency, %
Histology
ADC 192 58.72
SCLC 26 7.95
SCC 109 33.33
Sex
NA 26 7.95
Female 162 49.54
Male 139 42.51
Race
NA 26 7.95
Caucasian 265 81.04
Other 36 11.01
Type of smoker
NA 26 7.95
Current 82 25.08
Former 120 36.70
Never 97 29.66
Unknown 2 0.61
Pathologic M
NA 26 7.95
M0 295 90.21
M1 6 1.83
Pathologic N
NA 26 7.95
N0 212 64.83
N1 55 16.82
N2 34 10.40
Pathologic T
NA 26 7.95
T1 114 34.86
T2 160 48.93
T3 16 4.89
T4 11 3.36
ADC, adenocarcinoma; NA, not analyzed (low target expression); SCC,
squamous cell carcinoma; SCLC, small cell lung cancer; TMA, tissue
microarray.
IL-11R Targeting in Lung CancerStatistical Analysis
To analyze IHC data, Wilcoxon signed rank tests were
conducted to compare expressions of IL-11R in tumor
specimens with nonmalignant bronchial epithelium. Linear
regression models for continuous variables assuming a
normal distribution and logistic regression models for binary
variables were used to study the association of IL-11R
expression with histology for all of the cohort patients. For
patients with NSCLC (n Z 301), either linear regression
models or logistic regression models were built to charac-
terize the association between IL-11R expression and clin-
ical factors, including tumor pathology and smoking history.
Regression analyses of survival data based on the Cox
proportional hazards model were conducted on overall
survival, defined as time from surgery to death or to the end
of the study. The Student’s t-test was applied to analyze all
of the other data. All of the statistical tests were two-sided.
P values < 0.05 were considered statistically significant.
Statistical analyses were performed with the Prism software
version 5.0 (GraphPad Software, Inc.).
Results
IL-11R Is a Molecular Target in Human NSCLC
To begin to define the feasibility of a BMTP-11ebased
therapy in human lung cancer, we first examined the
expression of IL-11R in a panel (n Z 41) of primary
formalin-fixed paraffin-embedded tumors by IHC with a
specific antieIL-11Ra antibody. This analysis revealed high
cytoplasmic positivity in both SCC (Figure 1, AeC) and
ADC (Figure 1D). In samples with grade 3þ cytoplasmic
positivity, we also observed membrane IL-11R staining and
grade 3þ positivity in blood vessels into the tumor stroma
(Figure 1, E and F). For a subset of patient-derived samples
(n Z 18), matching nonmalignant lung tissues were alsoNormal
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Figure 2 IL-11R expression scores in tumor and adjacent nonmalignant
tissue. Comparison of the cytoplasm expression scores between lung cancer
and matched adjacent nonmalignant bronchial epithelium. n Z 18 lung
cancer samples; n Z 18 nonmalignant bronchial epithelium samples.
*P < 0.01.
The American Journal of Pathology - ajp.amjpathol.orgavailable; the expression of IL-11R in these tumor-adjacent
lung tissues was comparable with that in lung tissue from a
healthy donor (Figure 1G), except for a specific region
corresponding to the bronchiolar wall below the basement
membrane (Figure 1H). Cytoplasmic IL-11R levels were
quantified and compared between tumor and nonmalignant
tissues (Figure 2), confirming the observed higher expres-
sion in tumor cells (P Z 0.003).
These promising results prompted us to extend the analysis
to a larger panel of lung cancer tissue microarray specimens
(pilot, n Z 327) (Table 1, Supplemental Table S1). In this
cohort of patients, the cytoplasmic levels of IL-11R were
significantly higher in NSCLC than in SCLC (ADC or SCC
versus SCLC, P < 0.0001) (Table 2). The successive ana-
lyses were therefore focused exclusively on NSCLC samples
(n Z 301). The presence of IL-11R on the cell membrane
was evaluated in 200 cells/tissue sections, revealing well-
detectable positivity in approximately 25% of the cases.
These same samples also exhibited higher cytoplasmic levels2165
Table 2 Correlation of IL-11R Cytoplasmic Expression with Tumor Histology
Variable DF Estimate SEM
Wald 95% confidence limits
c2 P > c2Lower Upper
Intercept 1 109.7222 13.6401 82.9880 136.4564 64.71 <0.001
Histology
ADC 1 24.0349 14.3245 4.0405 52.1104 2.82 0.0934
SCC 1 6.6667 14.7330 22.2096 35.5429 0.20 0.6509
SCLC 0 0.0000 0.0000 0.0000 0.0000
Scale 1 57.8702 2.3586 53.4273 62.6827
ADC, adenocarcinoma; DF, degrees of freedom; SCC, squamous cell carcinoma; SCLC, small cell lung cancer.
Table 4 Membrane Expression of IL-11R in Human Lung Cancer
Cell Lines
þ
Cardó-Vila et alof IL-11R (P < 0.0001) (Table 3), suggesting that increased
overall expression of IL-11R favors its allocation to the
plasma membrane, where it can be targeted by ligand-
directed therapeutic agents (such as BMTP-11). Then, to
determine whether a subset of patients would specifically
benefit from BMTP-11 therapy, we first assessed IL-11R
expression in association to specific clinicopathologic fea-
tures. This analysis revealed that patients with ADC had
higher cytoplasmic levels of IL-11R than patients with SCC
(P < 0.0001), and patients who had ever smoked (either
former or current) had higher cytoplasmic levels of IL-11R
than patients who never smoked (P Z 0.005) (Table 3).
These findings encourage the use of increased expression of
IL-11R as a biomarker to identify patients who might benefit
from IL-11Retargeted therapy.
BMTP-11 Is Pharmacologically Active against Human
Lung Cancer Cells in Vitro
Having determined the pathologic presence of IL-11R as a
molecular target in lung cancer, we next evaluated the
activity of BMTP-11 as a ligand-directed therapy in tissue
culture and preclinical mouse models. We used the human
lung cancer-derived cell lines A549, H226, H460, HOP62,
and HOP92. All these NSCLC lines express IL-11R
on their cell surface membranes as evaluated by flow
cytometry (Table 4). H522 cells were used as a negative
control, showing undetectable surface expression of IL-11R.
Cultured cells were treated with serial concentrations of
BMTP-11 or untargeted D[KLAKLAK]2 (control), followed
by evaluation of both viability (by WST-1 assay at 18 hours
after treatment) and apoptosis (by Annexin V/PI assay at 6
hours after treatment). Plots were fitted to reverse sigmoidal
dose-response curves, showing that BMTP-11 reduced cell
viability by inducing apoptosis in all tumor cell linesTable 3 Associations between IL-11R Expression and Tumor
Clinicopathologic Features
Source DF c2 P > c2
IL-11R localization 1 23.56 <0.001
Histology 1 15.62 <0.001
Type of smoker 2 10.49 0.0053
DF, degrees of freedom.
2166examined (Figure 3, AeE). H460 (Figure 3A), HOP62
(Figure 3B), and HOP92 (Figure 3C) cells exhibited almost
no residual viability when treated with 100 mmol/L BMTP-
11, while retaining approximately 100% viability in the
presence of equimolar amounts of the control peptide
(P < 108). Similar results were obtained with H226
(Figure 3D) and A549 (Figure 3E) cells at higher BMTP-11
concentrations (100 to 300 mmol/L). No effect was observed
in the IL-11R cell line H522 (Figure 3F). In all other tumor
cell lines examined, the IC50 for BMTP-11 was 6.3- to
11.5-fold lower than the control (Table 5). These results
show that BMTP-11 is active against IL-11Reexpressing
human lung cancer cells in vitro, with the advantage of
suitable dose range, wide therapeutic window, and broad
applicability in cells derived from different lung cancer
types.
BMTP-11 Inhibits Tumor Growth in Vivo
To evaluate whether BMTP-11 can target tumors and exert
antitumor activity in vivo, we set up two preclinical models,
obtained by injection of H460 cells into the flank (subcu-
taneous xenograft) or through the tail vein (lung coloniza-
tion model) of immunodeficient mice. The expression of
IL-11R was assessed by IHC, confirming, in both models,
the high levels observed in clinical samples (Figure 4, A and
B) and the presence on the cell surface (Figure 4B). We
administered systemic BMTP-11 treatment to subcutaneous
tumor xenograft-bearing mice, followed by evaluation of
tumor volumes. The therapeutic effect of BMTP-11 was
tested on two cohorts of mice randomized in the followingCell lines
IL-11R cells, %
Anti-human IL-11R Control Ab
H460 10.3 0.3
HOP62 2.2 0.3
HOP92 3.4 0.3
H226 20.6 0.4
A549 12.2 0.3
H522 0.0 0.3
Ab, antibody.
ajp.amjpathol.org - The American Journal of Pathology
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Figure 3 In vitro pharmacologic activity of BMTP-11 on lung cancer cell lines. Cells were treated with serial molar concentrations of BMTP-11 or non-
targeted D[KLAKLAK]2 peptide (control). AeF: Viability was assessed by WST-1 assay at 18 hours after treatments (right panels). Apoptosis was evaluated by
Annexin V staining at 6 hours after treatments (left panels). Reverse sigmoidal curves in logarithmic scale for H460 (A), HOP62 (B), HOP92 (C), H226 (D),
A549 (E), and H522 (F) treated with BMTP-11 or control. RFU, relative fluorescence unit.
IL-11R Targeting in Lung Cancertreatment groups: BMTP-11 (n Z 10) or nontargeted
D[KLAKLAK]2 peptide (control, n Z 10). Mice were
injected intravenously with either compound on days 3 and
10 after tumor implantation, and tumor volumes were
measured every day until the end of the experiment (day
11). In this first preclinical trial, BMTP-11 induced a clear
delay in tumor growth compared with the untargeted
D[KLAKLAK]2 (control), which was significant after
treatment (P < 0.05) (Figure 4C). A similar treatment
regimen was applied to the lung colonization model, fol-
lowed by evaluation of total lung weight plus pulmonaryTable 5 Derived IC50 Values for Cell Viability and Relative
Efficacy
Cell lines
IC50 (mmol/L) Relative
efficacyBMTP-11 D(KLAKLAK)2
H460 33 208 6.3
HOP62 47 544 11.5
HOP92 83 572 6.9
H226 111 936 8.4
A549 120 >1000 >8.3
H522 972 >1000 w1.1
IC50, concentration that inhibits 50%.
The American Journal of Pathology - ajp.amjpathol.orgtumor count. In this second preclinical trial, administration
of BMTP-11 resulted in a reduction in total weight of the
lungs (P < 0.0001) (Figure 4D) and in the number of lung
tumors (P Z 0.002) (Figure 4E), yet another indication of
therapeutic efficacy. No tissue damage was observed by
histologic evaluation in the nonmalignant portion of the
lungs.
These results indicate that in both preclinical models,
BMTP-11 could effectively target the tumor site and inhibit
tumor growth.
Discussion
In this study, we evaluate IL-11R as an unrecognized
molecular target in lung cancer and also the efficacy of
targeting IL-11R with BMTP-11 in preclinical models of
tumor cell lines and tumor-bearing mice. First, we show that
IL-11R is highly and consistently expressed in a large panel
of surgical lung cancer specimens. Moreover, BMTP-11 is
therapeutically active in killing multiple lung cancer cell
lines in vitro. Finally, we show that BMTP-11 causes delay
in tumor growth in subcutaneous animal models of lung
cancer and a reduction in the establishment of tumors in a
lung colonization model.2167
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Figure 4 In vivo pharmacologic activity of BMTP-11 in subcutaneous and lung colonization mouse models of human lung cancer. IL-11R expression was
evaluated in the mouse models by immunohistochemistry. A: Representative subcutaneous tumor (left) and corresponding control staining with secondary
antibody only (right). B: Lung tumor (left) with evidence of membrane IL-11R staining (left, arrows). C: Effect of BMTP-11 treatment on the growth of
subcutaneous primary tumors. Mice received an intravenous administration of 10 mg/kg BMTP-11 or nontargeted D[KLAKLAK]2 peptide (control) on days 3 and
10 (arrows). D: Lung weights of mice injected into the tail vein with lung cancer cells and treated with BMTP-11 or control peptide. E: Number of tumors in
bilateral lungs dissected from mice treated with either BMTP-11 or control peptide. Data are expressed as mean tumor volumes  SEM (C). nZ 10 treated mice
(CeE); n Z 10 control mice (C); n Z 9 treated mice (D and E); *P < 0.05, **P < 0.01. Scale bars: 100 mm (A and B).
Cardó-Vila et alHigh expression of the IL-11R-native ligand, IL-11, has
been associated with lung cancer31,32 and with the capacity
of tumor cells to metastasize to the lungs,33 suggesting a
functional role in this specific pathologic setting and
encouraging the exploitation of IL-11R as a potential ther-
apeutic target. We show that IL-11R is overexpressed in
human specimens of primary lung cancer, in which high
cytoplasmic levels are associated with receptor presence on
the cell membrane. This accumulation of IL-11R at the cell
membrane was actually observed also in other cancers,
including gastric and colorectal carcinoma.17,18 In this light,
and because it might be difficult to assess membrane
localization in the presence of overwhelming cytoplasmic
staining, we propose to adopt the overall expression of
IL-11R as a biomarker of potential response to BMTP-11.
Confirming the robust specificity of IL-11R targeting in
the tumor, here we report low, cytoplasm-confined levels of
IL-11R in human nonmalignant bronchiolar epithelium. It is
therefore conceivable that in normal tissue this target is not
accessible by an extracellular ligand-directed drug, and, as a
consequence, no toxicity is expected to affect the adjacent,
nonmalignant lung tissue. This prerequisite is indeed
confirmed by our present study and past findings. BMTP-11
has been described as an effective treatment for advanced
osteosarcoma, including pulmonary metastasis.16 In this
study, no in vivo accumulation of BMTP-11 and no damage
to nonmalignant lung tissue were described. So far, the only
known BMTP-11 toxicity is a dose-dependent, reversible2168nephrotoxicity, reported in a first-in-man (phase 0) clinical
trial in cancer patients.22
Here, we also provide evidence of BMTP-11 antitumor
activity against lung cancer in vitro and in vivo. In vitro, the
observed IC50 for the effects of the targeted drug on cell
viability (33 to 120 mmol/L) are quite promising, also
considering that only a portion (2% to 21%) of cultured lung
cancer cells was positive for detectable surface membrane
expression of IL-11R. These effects are attributable to
BMTP-11emediated induction of apoptosis, as we previ-
ously reported in prostate cancer cell lines,20 and in leuke-
mia and lymphoma cell lines.21 In vivo, BMTP-11 was
effective in repressing tumor growth both in a subcutaneous
tumor xenograft and in a lung colonization model at rela-
tively low molar doses (10 mg/kg). The higher efficacy of
this drug in vivo is possibly related to an increased
expression of IL-11R by cancer cells and/or to the observed
presence in the vasculature in the tumor stroma. Although
such a mechanism will need further validation, one might
speculate that BMTP-11 would exert a synergistic effect by
acting on both tumor components and on the tumor
vasculature.Conclusions
We propose BMTP-11 as a candidate drug that should be
clinically evaluated in lung cancer patients. Meanwhile, aajp.amjpathol.org - The American Journal of Pathology
IL-11R Targeting in Lung Cancerpreference for higher scoring in ADC or smokers may help
to select subjects with increased expression of IL-11R who
would most benefit from IL-11Retargeted therapy,
although further investigation is needed. Our results also
introduce a new molecular marker of human NSCLC and
provide a translational avenue for targeted treatment of pa-
tients. Given the ongoing success of translating approved
molecularly targeted drugs to additional subsets of cancer
patients and the preclinical and pathologic data reported
here, we believe that BMTP-11 is a strong candidate drug
for a similar translational path.
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